Chemoprevention of Gastric Cancer: Role of COX-2 Inhibitors and Other Agents

2004 ◽  
Vol 22 (4) ◽  
pp. 320-326 ◽  
Author(s):  
Gerardo Nardone ◽  
Alba Rocco
Keyword(s):  
Gastric Cancer ◽  
Cox 2 ◽  
Cox 2 Inhibitors

The role of celecoxib as a potential inhibitor in the treatment of inflammatory diseases - a review

2021 ◽  
Vol 28 ◽  
Author(s):  
Josiane Viana Cruz ◽  
Joaquín María Campos Rosa ◽  
Njogu Mark Kimani ◽  
Silvana Giuliatti ◽  
Cleydson Breno Rodrigues dos Santos
Keyword(s):  
Side Effects ◽  
Inflammatory Diseases ◽  
Structural Basis ◽  
Potential Inhibitor ◽  
Cyclooxygenase 1 ◽  
Inflammatory Drugs ◽  
Cox 2 ◽  
Anti Inflammatory ◽  
Cox 2 Inhibitors

: This article presents a simplified view of celecoxib as a potential inhibitor in the treatment of inflammatory diseases. The enzyme cyclooxygenase (COX) has, predominantly, two isoforms called cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2). The former plays a constitutive role that is related to homeostatic effects in renal and platelets, while the latter is mainly responsible for induction of inflammatory effects. Since COX-2 plays an important role in the pathogenesis of inflammatory diseases, it has been signaled as a target for the planning of anti-inflammatory intermediates. Many inhibitors developed and planned for COX-2 inhibition have presented side effects to humans, mainly in the gastrointestinal and/or cardiovascular tract. Therefore, it is necessary to design new potential COX-2 inhibitors, which are relatively safe and without side effects. To this end, of the generation of non-steroidal anti-inflammatory drugs from “coxibs”, celecoxib is the only potent selective COX-2 inhibitor that is still commercially available. Thus, the compound celecoxib became a commercial prototype inhibitor for the development of anti-inflammatory agents for COX-2 enzyme. In this review, we provide highlights where such inhibition should provide a structural basis for the design of promising new non-steroidal anti-inflammatory drugs (NSAIDs) which act as COX-2 inhibitors with lesser side effects on the human body.

Effects on the lungs: role of COX-2 inhibitors

2004 ◽  
pp. 195-212
Author(s):  
R. Stokes Peebles ◽  
Koichi Hashimoto
Keyword(s):  
Cox 2 ◽  
Cox 2 Inhibitors

Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice

1998 ◽  
Vol 274 (6) ◽  
pp. G1061-G1067 ◽  
Author(s):  
Hitoshi Sawaoka ◽  
Sunao Kawano ◽  
Shingo Tsuji ◽  
Masahiko Tsujii ◽  
Edhi S. Gunawan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Cells ◽  
Nude Mice ◽  
Tumor Volume ◽  
Malignant Tumors ◽  
Apoptotic Cell ◽  
Dependent Manner ◽  
Cox 2 ◽  
Induced Apoptosis ◽  
Cox 2 Inhibitors

To clarify the role of mitogen-inducible cyclooxygenase (COX-2) in the development of malignant tumors, we investigated the effects of COX-2 inhibitors on the growth of gastric cancer xenografts in nude mice in vivo. MKN45 gastric cancer cells (5 × 106cells/animal) that overexpress COX-2 were inoculated subcutaneously into athymic mice. NS-398, a specific COX-2 inhibitor, or indomethacin, a nonspecific COX-2 inhibitor, was administered orally to animals every day for 20 days. These drugs reduced the tumor volume significantly. Immunohistochemistry using bromodeoxyuridine, nick end labeling, and electron microscopy showed that NS-398 induced apoptosis in cancer cells in a dose-dependent manner and inhibited cancer cell replication slightly. Indomethacin also induced apoptosis and suppressed replication of tumor cells. There was a significant negative correlation between tumor volume and apoptotic cell number within the tumor. These results are consistent with the hypothesis that COX-2 inhibitors suppress growth of gastric cancer xenografts mainly by inducing apoptosis and suppressing replication of the neoplastic cells. It follows that COX-2 plays an important role in the development of gastric cancer.

The clinical role of COX-2 inhibitors

2000 ◽  
Vol 118 (3) ◽  
pp. 639-640
Author(s):  
Gerson T. Lesser
Keyword(s):  
Clinical Role ◽  
Cox 2 ◽  
Cox 2 Inhibitors

scholarly journals Nonsteroidal Anti-Inflammatory Drugs: A Potential Pharmacological Treatment for Intracranial Aneurysm

2019 ◽  
Vol 9 (1) ◽  
pp. 31-45 ◽  
Author(s):  
Courtney L. Fisher ◽  
Stacie L. Demel
Keyword(s):  
Nuclear Factor Κb ◽  
High Morbidity ◽  
Surgical Interventions ◽  
Inflammatory Drugs ◽  
Cox 2 ◽  
Anti Inflammatory ◽  
Factor Α ◽  
Wall Sheer Stress ◽  
Cox 2 Inhibitors

Background: Saccular intracranial aneurysms (IAs) are outpouchings of the vessel wall of intracranial arteries. Rupture of IAs results in subarachnoid hemorrhage which is associated with high morbidity and mortality. Surgical interventions, such as clipping and coiling, have associated risks. Currently, there are no proven pharmacological treatments to prevent the growth or rupture of IAs. Infiltration of proinflammatory cytokines in response to increased wall sheer stress is a hallmark of IA. Nonsteroidal anti-inflammatory drugs (NSAIDs) are being investigated as potential therapeutic agents for reduction in growth and/or prevention of IA through inhibition of inflammatory pathways. Summary: This review will discuss the role of NSAIDs in attenuating the inflammation that drives IA progression and rupture. There are two main subtypes of NSAIDs, nonselective COX and selective COX-2 inhibitors, both of which have merit in treating IA. Evidence will be presented which shows that NSAIDs inhibit several key inflammatory mediators involved in IA progression including nuclear factor-κB, tumor necrosis factor-α, and matrix metalloproteinases. In addition, the role of NSAIDs in limiting inflammatory cell adhesion to endothelial cells and attenuating endothelial cell senescence will be discussed. Key Messages: There is an abundance of basic science and preclinical data that support NSAIDs as a promising treatment for IA. Additionally, a combination treatment strategy of low-dose aspirin given concomitantly with a selective COX-2 inhibitor may result in a reduced side effect profile compared to aspirin or selective COX-2 inhibitor use alone. Several large clinical trials are currently planned to further investigate the efficacy of NSAIDs as an effective nonsurgical treatment for IAs.

scholarly journals COX-2 Inhibitors and Gastric Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Zhen Wang ◽  
Jun-qiang Chen ◽  
Jin-lu Liu
Keyword(s):  
Gastric Cancer ◽  
Antitumor Agents ◽  
Prostaglandin E ◽  
Potential Toxicity ◽  
Chemopreventive Agents ◽  
Treatment Regimens ◽  
Cox 2 ◽  
Cox 2 Inhibitors ◽  
Cancer Studies ◽  
Selection Of

The evidence that cyclooxygenase-2 (COX-2) is upregulated and plays an important role in carcinogenesis of gastric cancer has triggered the topic of COX-2 inhibitors as chemopreventive agents for gastric cancer. Studies find that COX-2 inhibitors are associated not only with chemoprophylactic effects, but also with chemotherapeutic potentials in gastric cancer. Both COX-dependent and COX-independent pathways have a role in the anticancer efficiency of COX-2 inhibitors. However, enthusiasm is thwarted by the potential toxicity, that is, gastrointestinal toxicity of nonselective COX-2 inhibitors and cardiovascular risk of selective COX-2 inhibitors. Therefore, more studies are needed to develop new targeted antitumor agents (such as prostaglandin E receptor antagonist) and to define fundamental questions such as optimal treatment regimens, integration of cotherapy, and careful selection of candidates.

Silencing of Long Non-Coding RNA Myocardial Infarction-Associated Transcript Suppresses Progression of Gastric Cancer

2019 ◽  
Vol 9 (5) ◽  
pp. 637-645
Author(s):  
Lei Wang ◽  
Qi Hu ◽  
Feng Gu
Keyword(s):  
Gastric Cancer ◽  
G1 Phase ◽  
Migration And Invasion ◽  
Protein Levels ◽  
Cycle Arrest ◽  
Non Coding Rna ◽  
Cox 2 ◽  
Cell Arrest ◽  
Long Non Coding Rna

Background: Long noncoding RNAs (lncRNAs) have been consistently demonstrated to be involved in gastric cancer (GC) as either tumor oncogenes or tumor suppressors. However, the detailed role of MIAT in GC remains poorly understood. Methods: The expression of MIAT in GC tissues was measured by In situ hybridization (ISH) assay. Cell proliferation, apoptosis, cycle, migration and invasion assays were performed to analyze the biological functions of MIAT in GC cells. Besides, western blotting was used to evaluate the role of MIAT in the expressions of P16, COX-2 and MMP-9. Results: In the present study, we identified that MIAT was up-regulated in GC tissues. Furthermore, silencing MIAT significantly suppressed GC cells proliferation, migration and invasion, promoted GC cells apoptosis, and induced GC cells cycle arrest in G1 phase. Additionally, knockdown of MIAT notably up-regulated the protein level of P16 and down-regulated the protein levels of COX-2 and MMP-9. Conclusion: These observations imply that silencing MIAT inhibits the proliferation, migration and invasion, promotes apoptosis, and induces cell arrest in G1 phase, partially through up-regulating the expression level of P16 and down-regulating the expression levels of COX-2 and MMP-9, indicating that MIAT may a novel biomarker and therapeutic target for GC.

The Role of Cox-2 Inhibitors in Therapy

2007 ◽  
Vol 22 (9) ◽  
pp. 1-8
Author(s):  
Fadia T. Shaya
Keyword(s):  
Cox 2 ◽  
Cox 2 Inhibitors
Sign in / Sign up

Export Citation Format

Share Document